Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Given Average Recommendation of “Moderate Buy” by Analysts

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) has received an average recommendation of “Moderate Buy” from the thirteen brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, eight have given a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $17.25.

Several research firms have weighed in on AMLX. Citigroup increased their target price on Amylyx Pharmaceuticals from $12.00 to $20.00 and gave the company a “buy” rating in a research note on Friday, October 17th. Wall Street Zen lowered Amylyx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, December 20th. HC Wainwright increased their price target on shares of Amylyx Pharmaceuticals from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Robert W. Baird lifted their price objective on shares of Amylyx Pharmaceuticals from $10.00 to $19.00 and gave the stock an “outperform” rating in a research note on Thursday, October 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Amylyx Pharmaceuticals in a report on Monday, December 29th.

Amylyx Pharmaceuticals Stock Performance

AMLX opened at $15.76 on Friday. The company has a fifty day moving average price of $13.40 and a two-hundred day moving average price of $11.92. The firm has a market capitalization of $1.73 billion, a PE ratio of -8.76 and a beta of -0.31. Amylyx Pharmaceuticals has a 52 week low of $2.60 and a 52 week high of $17.49.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.06. Equities analysts forecast that Amylyx Pharmaceuticals will post -2.2 EPS for the current year.

Insider Activity at Amylyx Pharmaceuticals

In other news, insider Camille L. Bedrosian sold 6,580 shares of the business’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $14.35, for a total value of $94,423.00. Following the completion of the transaction, the insider owned 175,756 shares of the company’s stock, valued at $2,522,098.60. The trade was a 3.61% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Justin B. Klee sold 1,995 shares of the company’s stock in a transaction on Friday, January 16th. The shares were sold at an average price of $13.89, for a total transaction of $27,710.55. Following the completion of the sale, the chief executive officer owned 3,379,398 shares of the company’s stock, valued at approximately $46,939,838.22. This represents a 0.06% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 157,783 shares of company stock valued at $2,122,808. 12.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Large investors have recently modified their holdings of the business. Adage Capital Partners GP L.L.C. grew its position in shares of Amylyx Pharmaceuticals by 54.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 8,800,000 shares of the company’s stock worth $56,408,000 after purchasing an additional 3,102,395 shares in the last quarter. Perceptive Advisors LLC boosted its stake in shares of Amylyx Pharmaceuticals by 0.4% in the second quarter. Perceptive Advisors LLC now owns 7,902,365 shares of the company’s stock valued at $50,654,000 after buying an additional 28,017 shares during the period. TCG Crossover Management LLC boosted its stake in shares of Amylyx Pharmaceuticals by 5.0% in the third quarter. TCG Crossover Management LLC now owns 6,243,812 shares of the company’s stock valued at $84,853,000 after buying an additional 300,000 shares during the period. Vanguard Group Inc. grew its position in Amylyx Pharmaceuticals by 17.2% during the third quarter. Vanguard Group Inc. now owns 5,273,750 shares of the company’s stock worth $71,670,000 after buying an additional 775,722 shares in the last quarter. Finally, Commodore Capital LP acquired a new stake in Amylyx Pharmaceuticals during the third quarter worth approximately $55,386,000. 95.84% of the stock is currently owned by institutional investors.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc is a biopharmaceutical company dedicated to developing treatments for rare and debilitating neurological diseases. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company focuses on leveraging novel approaches to target cellular pathways implicated in neurodegeneration. Amylyx’s research platform centers on small-molecule therapies designed to protect neurons and support cellular health in patients with conditions that currently have limited or no disease-modifying treatment options.

The company’s lead product, AMX0035, is marketed under the trade name Relyvrio following U.S.